阿帕替尼联合紫杉醇及奈达铂方案治疗复发性宫颈鳞癌的疗效观察

Efficacy of apatinib combined with paclitaxel and nedaplatin in the treatment of recurrent cervical squamous cell carcinoma

目的探讨阿帕替尼联合紫杉醇及奈达铂方案治疗复发性宫颈鳞癌的安全性和有效性。方法收集2018年3月至2019年3月就诊于郑州大学第一附属医院的40例复发性宫颈鳞癌患者,按治疗方法分为2组,每组20例,对照组患者给予紫杉醇及奈达铂方案化疗,实验组患者在给予紫杉醇及奈达铂方案化疗基础上,加用甲磺酸阿帕替尼片,比较2组的疗效及不良反应发生情况。结果实验组客观缓解率、疾病控制率分别为65.0%、90.0%,高于对照组的40.0%、75.0%,差异均有统计学意义(χ^(2)=2.506,P=0.113;χ^(2)=0.693,P=0.049)。实验组中位疾病无进展生存时间为7.4个月(95%CI为5.9~8.9个月),优于对照组的5.7个月(95%CI为4.4~7.0个月),差异有统计学意义(χ^(2)=4.387,P=0.036)。实验组蛋白尿发生率为30.0%,高于对照组的0.0%,差异有统计学意义(χ^(2)=4.902,P=0.027)。结论阿帕替尼联合紫杉醇及奈达铂方案治疗复发性宫颈癌安全有效。

Objective To investigate safety and efficacy of apatinib combined with paclitaxel and nedaplatin in the treatment of recurrent cervical squamous cell carcinoma.Methods Forty patients with recurrent cervical squamous cell carcinoma treated in the First Affiliated Hospital of Zhengzhou University from March 2018 to March 2019 were divided into two groups according to the treatment method.The patients in the control group were treated with paclitaxel and nedaplatin regimen,and the patients in the experimental group were treated with paclitaxel and nedaplatin plus apatinib mesylate tablets.The effects and adverse reactions of the two groups were compared.Results The objective response rate,disease control rate in the experimental group were respectively 65.0%and 90.0%,and were 40.0%and 75.0%in the control group(χ^(2)=2.506,P=0.113;χ^(2)=0.693,P=0.049).The median progression free survival of the experimental group was 7.4 months(95%CI:5.9~8.9 months),and was 5.7 months(95%CI:4.4~7.0 months)of the control group(χ^(2)=4.387,P=0.036).The incidence of proteinuria in the experimental group(30.0%)was higher than that in the control group(0.0%;χ^(2)=4.902,P=0.027).Conclusion Apatinib combined with paclitaxel and nidaplatin is safe and effective in the treatment of recurrent cervical cancer,which needs larger clinical trials to confirm.